Clinically, monoclonal antibodies against mTOR, such as rapamycin, are used in BC to reduce chemoresistance but have been demonstrated to have various negative systemic side effects which may be explained by their inhibitory effect on mTOR autophagy in physiological tissues, thereby attenuating cell vitality [216]. Here, MTOR is linked to breast cancer.